Axsome Therapeutics (AXSM) Financial Analysis & Valuation | Quarter Chart
Axsome Therapeutics (AXSM)
AXSMPrice: $241.12
Fair Value: 🔒
🔒score
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depre... more
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapie... more
Description
Shares
| Market Cap | $12.41B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Herriot Tabuteau |
| IPO Date | 2015-11-19 | CAGR | — |
| Employees | 712 | Website | www.axsome.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
AXSM chart loading...
Fundamentals
Technicals
| Enterprise Value | $8.83B | P/E Ratio | -62.96 |
| Forward P/E | 40.89 | PEG Ratio | — |
| P/S Ratio | 17.9 | P/B Ratio | 231.09 |
| P/CF Ratio | -178.35 | P/FCF Ratio | -178.58 |
| EPS | $-3.83 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 63.88% | Gross Margin | 0.93% |
| Operating Margin | -0.25% | Profit Margin | -0.27% |
| ROE | -2.6% | ROA | -0.26% |
| ROCE | -0.64% | Current Ratio | 1.39 |
| Quick Ratio | 1.32 | Cash Ratio | 0.69 |
| Debt/Equity | 3.97 | Interest Coverage | -33.07 |
| Altman Z Score | 9.05 | Piotroski Score | 4 |